← Leaderboards
Xin Chen
University Of Hawaii At Manoa
$14,864,120
Attributed
$19,470,350
Total exposure
23
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,470,350 · 23
By mechanism
R01$13,806,189 · 6
R21$2,863,176 · 8
R03$779,741 · 5
K01$722,250 · 1
UG3$657,145 · 1
R43$348,747 · 1
Top collaborators
- Satdarshan Singh Monga11 shared
- Robert F. Schwabe5 shared
- Shugeng Cao2 shared
- Andreas Stahl2 shared
- Xu Wu2 shared
- Yong Huang1 shared
Most similar at University Of Hawaii At Manoa
Same institution · by research overlap
- Satdarshan Singh Monga$23,652,966
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsPathway InteractionsTumorIn VivoSamplingLiverMolecularMalignant Neoplasm Of LiverPrimary Carcinoma Of The Liver CellsSignal TransductionPathogenesisIn VitroLiver NeoplasmsOncogenesMediatingGenesSignal PathwayInsightMouse ModelCellsBaseOverexpressionIncidenceGene Expression
Grant awards (70)
Investigating multifactorial beta-catenin activation in hepatocellular cancers$490,219
R01 · FY2025 · CA · contact PI
Targeting CXCR2+ PMN-MDSCs for immunotherapy of hepatoblastoma$402,400
R21 · FY2025 · CA · contact PI
Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors$322,891
UG3 · FY2025 · CA
Cancer Biology Research Program$219,100
P30 · FY2025 · CA · contact PI
Investigating multifactorial beta-catenin activation in hepatocellular cancers$465,707
R01 · FY2024 · CA · contact PI
Signaling pathways during hepatocarcinogenesis$340,095
R01 · FY2024 · CA · contact PI
Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors$334,254
UG3 · FY2024 · CA
Cancer Biology Research Program$74,002
P30 · FY2024 · CA · contact PI
Investigating multifactorial beta-catenin activation in hepatocellular cancers$480,413
R01 · FY2023 · CA · contact PI
Signaling pathways during hepatocarcinogenesis$350,834
R01 · FY2023 · CA · contact PI
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma$609,144
R01 · FY2022 · CA
Signaling pathways during hepatocarcinogenesis$350,460
R01 · FY2022 · CA · contact PI
Investigating multifactorial beta-catenin activation in hepatocellular cancers$324,555
R01 · FY2022 · CA · contact PI
Investigating multifactorial beta-catenin activation in hepatocellular cancers$166,859
R01 · FY2022 · CA · contact PI
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma$621,575
R01 · FY2021 · CA
Investigating multifactorial beta-catenin activation in hepatocellular cancers$511,819
R01 · FY2021 · CA · contact PI
Signaling pathways during hepatocarcinogenesis$369,431
R01 · FY2021 · CA · contact PI
Cabozentinib based combination therapy for the treatment of hepatocellular carcinoma$80,750
R03 · FY2021 · CA · contact PI
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma$621,461
R01 · FY2020 · CA
Yap and beta-catenin interactions in liver: Implications in Pathophysiology$420,055
R01 · FY2020 · CA
Signaling pathways during hepatocarcinogenesis$368,669
R01 · FY2020 · CA · contact PI
Signaling cascades in cholangiocarcinoma development$362,569
R01 · FY2020 · CA · contact PI
Cabozentinib based combination therapy for the treatment of hepatocellular carcinoma$80,626
R03 · FY2020 · CA · contact PI
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma$601,544
R01 · FY2019 · CA
Yap and beta-catenin interactions in liver: Implications in Pathophysiology$407,169
R01 · FY2019 · CA
Signaling cascades in cholangiocarcinoma development$351,691
R01 · FY2019 · CA · contact PI
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma$634,470
R01 · FY2018 · CA
Yap and beta-catenin interactions in liver: Implications in Pathophysiology$416,268
R01 · FY2018 · CA
Signaling cascades in cholangiocarcinoma development$362,569
R01 · FY2018 · CA · contact PI
SWI/SNF complex in mouse HCC development$79,250
R03 · FY2018 · CA · contact PI
Inducible systems for studying liver tumor mainenance in vivo$79,250
R03 · FY2018 · CA · contact PI
Yap and beta-catenin interactions in liver: Implications in Pathophysiology$414,072
R01 · FY2017 · CA
Signaling cascades in cholangiocarcinoma development$362,569
R01 · FY2017 · CA · contact PI
SWI/SNF complex in mouse HCC development$79,250
R03 · FY2017 · CA · contact PI
Inducible systems for studying liver tumor mainenance in vivo$79,250
R03 · FY2017 · CA · contact PI
Yap and beta-catenin interactions in liver: Implications in Pathophysiology$425,315
R01 · FY2016 · CA
Signaling cascades in cholangiocarcinoma development$362,569
R01 · FY2016 · CA · contact PI
Molecular Genetics of Liver Cancers$356,625
R01 · FY2016 · CA · contact PI
Glutamine catabolism in c-Myc driven liver tumor development$206,843
R21 · FY2016 · CA · contact PI
Molecular Genetics of Liver Cancers$356,625
R01 · FY2015 · CA · contact PI
Fatty acid transporters in cholangiocarcinoma pathogenesis$205,864
R21 · FY2015 · CA · contact PI
Glutamine catabolism in c-Myc driven liver tumor development$172,324
R21 · FY2015 · CA · contact PI
Molecular Genetics of Liver Cancers$355,688
R01 · FY2014 · CA · contact PI
Fatty acid transporters in cholangiocarcinoma pathogenesis$171,010
R21 · FY2014 · CA · contact PI
Molecular Genetics of Liver Cancers$13,000
R01 · FY2014 · CA · contact PI
Molecular Genetics of Liver Cancers$287,938
R01 · FY2013 · CA · contact PI
Lipogenic inhibitors in prevention of oncogene induced liver cancer$72,615
R03 · FY2013 · CA · contact PI
Molecular Genetics of Liver Cancers$306,316
R01 · FY2012 · CA · contact PI
Genetic Alterations Promoting Alcohol Induced Hepatic Carcinogenesis$222,094
R21 · FY2012 · AA · contact PI
Virus-gene interactions during hepatic carcinogenesis$201,623
R21 · FY2012 · CA · contact PI
Lipogenic inhibitors in prevention of oncogene induced liver cancer$77,250
R03 · FY2012 · CA · contact PI
Molecular Genetics of Liver Cancers$306,316
R01 · FY2011 · CA · contact PI
Genetic Alterations Promoting Alcohol Induced Hepatic Carcinogenesis$183,469
R21 · FY2011 · AA · contact PI
Virus-gene interactions during hepatic carcinogenesis$168,019
R21 · FY2011 · CA · contact PI
Molecular Genetics of Liver Cancers$315,790
R01 · FY2010 · CA · contact PI
Targeted siRNA Delivery to Liver with EIT guided Sonoporation$348,747
R43 · FY2009 · AA
Molecular Genetics of Liver Cancers$315,790
R01 · FY2009 · CA · contact PI
A flexible somatic and sporadic mouse model for liver cancers$203,667
R21 · FY2009 · CA · contact PI
A flexible somatic and sporadic mouse model for liver cancers$168,905
R21 · FY2008 · CA · contact PI
Gene Expression Profiles in Human Liver Cancers$148,770
K01 · FY2007 · CA · contact PI
Gene Expression Profiles in Human Liver Cancers$148,770
K01 · FY2006 · CA · contact PI
Expression Programs of Intestinal Cell Differentiation$147,940
R21 · FY2006 · DK · contact PI
Hedgehog signaling in human hepatocellular carcinoma$127,228
R21 · FY2006 · CA · contact PI
Expression Programs of Intestinal Cell Differentiation$151,500
R21 · FY2005 · DK
Gene Expression Profiles in Human Liver Cancers$148,770
K01 · FY2005 · CA
Hedgehog signaling in human hepatocellular carcinoma$130,290
R21 · FY2005 · CA
Expression patterns of gastric premalignant lesions$75,750
R03 · FY2005 · CA
Gene Expression Profiles in Human Liver Cancers$148,770
K01 · FY2004 · CA
Expression patterns of gastric premalignant lesions$75,750
R03 · FY2004 · CA
Gene Expression Profiles in Human Liver Cancers$127,170
K01 · FY2003 · CA